Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
$225 million all-cash deal characterized as immediately accretive to 2013 adjusted diluted EPS, with Boca expected to generate approximately $50 million of…
The $225M deal at ~4.5x projected 2013 EBITDA was characterized as a disciplined niche-generics tuck-in extending Qualitest's controlled substances and…
FTC complaint required limited divestitures of overlapping ANDA products to preserve competition before clearing Endo's Boca Pharmacal acquisition — resolution…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Endo's Qualitest subsidiary to acquire Boca Pharmacal for ~$225M cash; added niche specialty generics (controlled substances, semisolids, solutions); expected $50M 2013 EBITDA.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo Health Solutions Inc. / Boca Pharmacal, LLC (this deal) | 2013 | $225M | 19 |
| Endo Health Solutions Inc. / Paladin Labs Inc. | 2013 | $1.6B | 28 |
| Endo Health Solutions Inc. / Boca Pharmacal, LLC | 2014 | $225M | 21 |
| Endo Health Solutions Inc. / NuPathe Inc. | 2013 | $271M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
← Browse all deals · How we score deals
More: 2013 deals · Endo Health Solutions Inc. deals · Other deals